On 24 July, President Trump signed an executive order proposing a reform that would ensure the Medicare program and US seniors pay no more for the most-costly Medicare Part B drugs than any economically comparable OECD country. The order takes effect in 30 days unless Congress acts. Until then, GlobalData is offering unique access to its pharmaceutical pricing database to allow domestically focused and global firms the opportunity to examine the potential impact of this watershed order.

To access the POLI trial, please provide your details and our team will contact you shortly upon submission.